Tokiyoshi Tanegashima

Radium-223 dichloride improves survival and delays symptomatic skeletal events in patients with bone-metastatic castration-resistant prostate cancer; however, therapeutic responses vary considerably among individuals, and predictive germline biomarkers remain undefined. We conducted a prospective multicenter genome-wide association study within the KYUCOG-1901 cohort to identify germline single-nucleotide polymorphisms associated with the clinical efficacy of radium-223.

AE Adverse event CI Confidence interval GWAS Genome-wide association study HR Hazard ratio ICI Immune checkpoint inhibitor OR Odds ratio PD-1 Programmed cell death-1 PD-L1 Programmed cell death-ligand 1 PFS Progression-free survival RCC Renal cell carcinoma SNP Single nucleotide polymorphism 1 Introduction Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) have brought significant advancements in the treatment of advanced renal...

AR androgen receptor C-CAT Center for Cancer Genomics and Advanced Therapeutics MSI microsatellite instability TMB tumor mutation burden 1 Introduction Prostate cancer was the second most commonly diagnosed malignancy among men worldwide in 2020, with an estimated 1.4 million new cases and approximately 375,000 deaths [1]. It is estimated that one in six men will be diagnosed with prostate cancer during their lifetime [1].